BACKGROUND: The efficacy and safety of a new transurethral endoscopic device using bipolar electrocautery, the Gyrus system, were evaluated. This system permits rapid prostate tissue removal by endoscopic vaporization with little bleeding using saline irrigation, therefore eliminating transurethral resection of the prostate (TURP) syndrome. METHODS: Between January 2000 and December 2006 a total of 401 patients with benign prostatic hyperplasia underwent transurethral resection of the prostate utilizing the Gyrus device. RESULTS: We did not observe intraoperative complications, secondary hemorrhage with postoperatively severe fall of haemoglobin or any differences in sodium concentrations. Mean peak flow rate increased from 8.5 preoperatively to 24.5 ml/s at 36 months and mean International Prostatic Symptom Score (IPSS) decreased from 18 preoperatively to 5 at 36 months. CONCLUSIONS: Our preliminary results with a bipolar electrode for electrovaporization of the prostate using the Gyrus suggest that it is a useful and safe endoscopic device.
BACKGROUND: The efficacy and safety of a new transurethral endoscopic device using bipolar electrocautery, the Gyrus system, were evaluated. This system permits rapid prostate tissue removal by endoscopic vaporization with little bleeding using saline irrigation, therefore eliminating transurethral resection of the prostate (TURP) syndrome. METHODS: Between January 2000 and December 2006 a total of 401 patients with benign prostatic hyperplasia underwent transurethral resection of the prostate utilizing the Gyrus device. RESULTS: We did not observe intraoperative complications, secondary hemorrhage with postoperatively severe fall of haemoglobin or any differences in sodium concentrations. Mean peak flow rate increased from 8.5 preoperatively to 24.5 ml/s at 36 months and mean International Prostatic Symptom Score (IPSS) decreased from 18 preoperatively to 5 at 36 months. CONCLUSIONS: Our preliminary results with a bipolar electrode for electrovaporization of the prostate using the Gyrus suggest that it is a useful and safe endoscopic device.
Authors: W D Dunsmuir; J P McFarlane; A Tan; C Dowling; J Downie; J Kourambas; S Donnellan; N Redgrave; R Fletcher; M Frydenberg; C Love Journal: Prostate Cancer Prostatic Dis Date: 2003 Impact factor: 5.554
Authors: Jens Rassweiler; Michael Schulze; Christian Stock; Dogu Teber; Jean De La Rosette Journal: Minim Invasive Ther Allied Technol Date: 2007 Impact factor: 2.442
Authors: M Falsaperla; L Cindolo; A Saita; A Polara; A Bonaccorsi; A Scavuzzo; M Motta; G Morgia Journal: Minerva Urol Nefrol Date: 2007-06 Impact factor: 3.720